Investors & Media International Stem Cell Corporation Announces 2024 Fourth Quarter and Year-End Results International Stem Cell Corporation Announces Strong Financial Results for the Quarter Ended March 31, 2022 International Stem Cell Corporation Announces 2021 Fourth Quarter and Year-End Results International Stem Cell Corporation Announces Successful Completion of Its Phase 1 Clinical Trial in Parkinson's Disease International Stem Cell Corporation Announces Financial Results for the Three and Nine-Months ended September 30, 2019 Special Invitation to Purchase ISCO's Advanced Joint Supplement at an Introductory Price International Stem Cell Corporation Announces Operating Results for the Quarter Ended March 31, 2019 International Stem Cell Corporation is Valued at $43 Million Market Value by Edison Investment Research International Stem Cell Corporation Completes Enrollment and Dosing in its Parkinson's Disease Clinical Trial International Stem Cell Corporation Announces 2018 Fourth Quarter and Year-End Results 1 2 3 4 5 6 << < > >>
